* Leap Therapeutics Inc LPTX.OQ reported quarterly
adjusted
earnings of 51 cents per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of $-3.20. The mean expectation of four analysts
for the quarter was for a loss of 58 cents per share. Wall
Street expected results to range from -64 cents to -56 cents per
share.
* Reported revenue was zero; analysts expected zero.
* Leap Therapeutics Inc's reported EPS for the quarter was
51
cents.
* The company reported a quarterly loss of $13.82 million.
* Leap Therapeutics Inc shares had risen by 4.5% this
quarter and
lost 32.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 4.1%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Leap Therapeutics
Inc is $12.00
This summary was machine generated from LSEG data May 13 at
01:31 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.58 0.51 Beat
Dec. 31 2023 -0.55 -0.46 Beat
Sep. 30 2023 -0.58 -0.51 Beat
Jun. 30 2023 -0.90 -0.91 Missed